Research Topics
Species | Rj SoifferSummaryAffiliation: Harvard University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplMarcelo C Pasquini
Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, USA
J Clin Oncol 30:3194-201. 2012..However, concerns about relapse, graft rejection, and variability in technique have limited the widespread application of this approach...
Immune modulation and chronic graft-versus-host diseaseRj Soiffer
Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, MA, USA
Bone Marrow Transplant 42:S66-S69. 2008..As efforts continue to devise strategies to treat and prevent chronic GVHD, it is important to acknowledge the link between cGVHD and freedom from relapse, at least for certain malignancies...
CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donorsR J Soiffer
Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Oncol 19:1152-9. 2001..Herein, we report results in the first 48 recipients of unrelated marrow using CD6+ TCD as the sole form of GVHD prophylaxis...- Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignanciesRobert J Soiffer
Dana Farber Cancer Institute, Boston, MA, USA
Blood 117:6963-70. 2011..001). Corresponding probabilities of overall survival were 50%, 38%, and 46% (P = .008). These data suggest adopting a cautious approach to routine use of in vivo T-cell depletion with RIC regimens... - Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusionRobert J Soiffer
Biol Blood Marrow Transplant 8:625-32. 2002..Our results indicate that CD8 depletion reduces the incidence of GVHD associated with DLI without adversely affecting conversion to donor hematopoiesis or immunologic recovery... - Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host diseaseV T Ho
Department of Medical Oncology, Biostatistics, Dana Farber Cancer Institute, Boston, MA 02115, USA
Bone Marrow Transplant 34:987-94. 2004..There was no correlation between CD8+ number and GVHD or survival. A 2-log depletion of CD8+ cells from PBSC is insufficient to prevent GVHD... - CD8+ cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot studyE P Alyea
Center for Hematologic Oncology, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Bone Marrow Transplant 34:123-8. 2004..The CD8-HDM Cell Separation System appears to be highly selective and effective in depleting CD8+ T cells from DLI apheresis products, and CD8-depleted DLI is capable of mediating a graft-versus-leukemia effect while minimizing GVHD... - Routine screening for psychosocial distress following hematopoietic stem cell transplantationS J Lee
Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Bone Marrow Transplant 35:77-83. 2005..Pre-transplant distress appears to be highly predictive of distress post transplant and is a feasible marker to target screening and intervention programs... - Preinfusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantationR L Haspel
Department of Pathology, Beth Israel Deaconess Medical Centre, Boston, MA 02115, USA
Bone Marrow Transplant 41:523-9. 2008.... - Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancyA M Saito
Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Bone Marrow Transplant 40:209-17. 2007..Our data suggest that substantially lower costs and fewer days of hospitalization within the first year after RICT procedures can be obtained with no compromise of long-term clinical outcomes compared to HDCT procedures... - HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantationV T Ho
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Bone Marrow Transplant 37:845-50. 2006..0001). Cumulative relapse incidence was 35% in the HLA-C-mismatched and 55% in the 10/10-matched cohort, P=0.09. HLA-C mismatch is associated with inferior survival after URD NST... - Prolonged impairment of very late activating antigen-mediated T cell proliferation via the CD3 pathway after T cell-depleted allogeneic bone marrow transplantationK Sugita
Division of Tumor Immunology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
J Clin Invest 94:481-8. 1994..Our results imply that disturbance of VLA function could explain, at least in part, the persistent immunoincompetent state after allo-BMT and may be involved in susceptibility to opportunistic infections after allo-BMT... - High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remissionA S Freedman
Division of Hematologic Malignancies and Biostatistics, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Oncol 16:13-8. 1998.... - Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplantE P Alyea
Divisions of Hematologic Malignancies and Biostatistics, Dana Farber Cancer Institute, Boston, MA, USA
Blood 91:3671-80. 1998.... - Recovery after stem-cell transplantation for hematologic diseasesS J Lee
Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Oncol 19:242-52. 2001.... - Quantitation of T-cell neogenesis in vivo after allogeneic bone marrow transplantation in adultsE P Hochberg
Disease Center for Hematologic Oncology, Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston MA 02115, USA
Blood 98:1116-21. 2001..These studies demonstrate that T-cell neogenesis contributes to immune reconstitution in adult patients and suggest that thymic function can be manipulated in vivo. (Blood. 2001;98:1116-1121).. - Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemiaC J Wu
Center for Hematologic Oncology, and Department of Biostatistical Science, Dana Farber Cancer Institute, and Department of Medicine, and Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
J Clin Invest 106:705-14. 2000..The characterization of B cell-defined antigens may help identify clinically relevant targets of the GVL response in vivo... - A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantationJ H Antin
Department of Adult Oncology and Biostatistical Science, Dana-Farber Cancer Institute, Boston, MA 02115, USA
Bone Marrow Transplant 29:373-7. 2002..The use of IL-11 as GVHD prophylaxis in allogeneic transplantation cannot be recommended as administered in this trial... - Altered tyrosine phosphorylation via the very late antigen (VLA)/beta1 integrin stimulation is associated with impaired T-cell signaling through VLA-4 after allogeneic bone marrow transplantationT Sato
Division of Tumor Immunology, Dana Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
Blood 90:4222-9. 1997.... - Quality of life associated with acute and chronic graft-versus-host diseaseS J Lee
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
Bone Marrow Transplant 38:305-10. 2006..The adverse effects of acute GVHD are detectable with the TOI at 6 months post transplantation after which development of chronic GVHD is the most strongly correlated with worse QOL... - Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromesP Armand
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Bone Marrow Transplant 45:877-85. 2010..We propose that this SCT-specific cytogenetics grouping scheme be used for patients with MDS or AML arising from MDS who are considering or undergoing SCT... - A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cellsE Zorn
Center for Hematologic Oncology, Dana-Farber Cancer Institute, Department of Medicine, Brigham and Women Hospital, Harvard Medical School, Boston, MA 02115, USA
Transplantation 71:1131-7. 2001..Based on these findings, CD4+ T cells with BCR-ABL specificity do not appear to be mediators of the anti-leukemia response in vivo after donor lymphocyte infusion... - Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantationV T Ho
Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
Biol Blood Marrow Transplant 7:223-9. 2001..Patients with pretransplantation FEV1 of < or = 80% appear to have a higher risk for SPCs... - CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemiaX F Yang
Center for Hematologic Oncology, Dana Farber Cancer Institute, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 98:7492-7. 2001..These findings suggest that CML66 may be immunogenic in a wide variety of malignancies and may be a target for antigen-specific immunotherapy... - R24 anti-GD3 ganglioside antibody can induce costimulation and prevent the induction of alloantigen-specific T cell clonal anergyV A Boussiotis
Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, MA 02115, USA
Eur J Immunol 26:2149-54. 1996..Our data indicate that the membrane ganglioside GD3 structure recognized by R24 may play an important role in antigen-specific T cell clonal response... - Post-transplant acute limbic encephalitis: clinical features and relationship to HHV6W W Seeley
Department of Neurology, Brigham and Women s Hospital, Boston, MA, USA
Neurology 69:156-65. 2007..Clinical and laboratory features of the syndrome, however, have not been well characterized... - IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivoEmmanuel Zorn
Division of Hematologic Malignancies, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
Blood 108:1571-9. 2006..Our findings support the clinical evaluation of low-dose IL-2 to selectively modulate CD4+CD25+ Tregs and increase expression of FOXP3 in vivo... - Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantationCorey Cutler
Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Blood 109:3108-14. 2007..Differences between MRD and URD cohorts are not evident when effective GVHD prophylaxis is used... - Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemiaJennifer R Brown
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
Biol Blood Marrow Transplant 12:1056-64. 2006.... - Chronic myelogenous leukemiaEllin Berman
J Natl Compr Canc Netw 3:732-55. 2005 - Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndromeEdwin P Alyea
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Biol Blood Marrow Transplant 12:1047-55. 2006..These results suggest that NST is a reasonable alternative for patients with advanced AML and MDS at high risk for complications after myeloablative transplantation... - Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantationPhilippe Armand
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Blood 109:4586-8. 2007..They also suggest future prospective trials to examine the potential benefit of chelation therapy in this setting... - High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trialsJohn Koreth
Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Biol Blood Marrow Transplant 13:183-96. 2007..01; 95% confidence interval, 1.64-5.50). Hence, evaluating alternative therapeutic options upfront may also be reasonable... - Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantationPhilippe Armand
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Biol Blood Marrow Transplant 13:655-64. 2007.... - Donor lymphocyte infusions for acute myeloid leukaemiaRobert J Soiffer
Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
Best Pract Res Clin Haematol 21:455-66. 2008.... - Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remissionRichard M Stone
Department of Medical Oncology, Division of Hematologic Malignancies, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
Am J Hematol 83:771-7. 2008..This study supports further investigation of immunotherapy in the post-intensive chemotherapy setting in the management of patients with AML... - Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantationEdwin P Alyea
Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Biol Blood Marrow Transplant 14:920-6. 2008.... - Recurrent acute promyelocytic leukemia presenting as a sacral nerve root massSantosh Kesari
Department of Neurology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA, USA
J Clin Oncol 26:3279-81. 2008 - Individual physician practice variation in hematopoietic cell transplantationStephanie J Lee
Division of Clinical Research, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D5 290, Seattle, WA 98109, USA
J Clin Oncol 26:2162-70. 2008..Previous studies have evaluated practice variation in hematopoietic cell transplantation (HCT) among transplant centers and countries. There are no studies investigating individual physician practice variation in HCT... - Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcomePhilippe Armand
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Biol Blood Marrow Transplant 14:418-25. 2008..These results emphasize the importance of lymphoma histology for patients undergoing RIC SCT, as well as the lack of relevance of donor chimerism for outcome in this patient population... - Costs of allogeneic hematopoietic cell transplantation with high-dose regimensAkiko M Saito
Division of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
Biol Blood Marrow Transplant 14:197-207. 2008..If no complications occurred, the mean cost within the first year was $79,222. These results provide cost estimates for complicated and uncomplicated HDCT procedures, as well as costs for management of specific transplant complications... - A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantationPhilippe Armand
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Biol Blood Marrow Transplant 14:28-35. 2008.... - High levels of B-cell activating factor in patients with active chronic graft-versus-host diseaseStefanie Sarantopoulos
Division of Hematologic Malignancies and Department of Medical Oncolog, Dana Farber Cancer Institute and Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
Clin Cancer Res 13:6107-14. 2007..Thus, we tested whether BAFF correlated with chronic GVHD disease activity and time of onset after allogeneic hematopoietic stem cell transplantation (HSCT)... - Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysisFrancisco M Marty
Division of Infectious Diseases, Boston, MA 02115, USA
Blood 110:490-500. 2007..66; P = .14 and P = .35, respectively). The protective effect of sirolimus-containing GVHD prophylaxis regimens on CMV reactivation should be confirmed in randomized trials... - Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemiaJohn G Gribben
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
Blood 106:4389-96. 2005..From these findings we have altered our approach for patients with high-risk CLL and are currently exploring the role of related and unrelated allogeneic SCT following reduced-intensity conditioning regimens... - Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myelomaRoberto Bellucci
Center for Hematologic Oncology and Department of Biostatistics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Blood 99:4610-7. 2002..05). These results provide evidence that prophylactic infusion of CD4(+) donor lymphocytes 6 months after BMT enhances reconstitution of donor T cells and conversion to donor hematopoiesis as well as promoting antitumor immunity... - Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort studyFrancisco M Marty
Division of Infectious Diseases and Hematopoietic Stem Cell Transpalntation Service, Brigham and Women s Hospital and Dana Farber Cancer Instiute, Harvard Medical School, Boston, MA 02115, USA
Blood 102:2768-76. 2003..Pre-emptive systemic antifungal therapy against molds should be considered in patients who develop severe GVHD after HSCT if infliximab is used... - Optimistic expectations and survival after hematopoietic stem cell transplantationStephanie J Lee
Department of Medical Oncology, and Center for Outcomes and Policy Research, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
Biol Blood Marrow Transplant 9:389-96. 2003..Our data suggest an association between more optimistic expectations and early survival following hematopoietic stem cell transplantation, but this association is not present by 6 months posttransplantation... - Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantationMartha Wadleigh
Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
Blood 102:1578-82. 2003..Three of 14 patients who received GO prior to SC transplantation died of VOD. We conclude that patients undergoing SC transplantation within a short interval from GO administration are at increased risk of developing VOD... - Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantationJoseph H Antin
Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
Blood 102:1601-5. 2003..This novel agent is worthy of further study in allogeneic transplantation... - Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantationEdwin P Alyea
Biol Blood Marrow Transplant 8:601-7. 2002..However, these adverse events do not lead to inferior probability of relapse-free survival because they are accompanied by a reduction in relapse rates... - Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantationDeborah C Molrine
Massachusetts Biologic Laboratories, University of Massachusetts Medical School, Jamaica Plain, MA 02130, USA
Blood 101:831-6. 2003..A 3-dose schedule of PCV7 vaccine at 3, 6, and 12 months is immunogenic in these patients regardless of donor immunization... - Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantationJoseph H Antin
Department of Medical Oncology and Biostatistical Science, Dana Farber Cancer Institute, Boston, MA 02115, USA
Blood 100:3479-82. 2002..We conclude that blockade of IL-1 using IL-1Ra during conditioning and 10 days immediately after transplantation is not sufficient to reduce GVHD or toxicity or to improve survival... - A novel rapid single nucleotide polymorphism (SNP)-based method for assessment of hematopoietic chimerism after allogeneic stem cell transplantationEphraim P Hochberg
Center for Hematologic Oncology and the Department of Biostatistics, Dana-Farber Cancer Institute, Boston, MA 02115, USA
Blood 101:363-9. 2003..SNP-based assessment of chimerism is a promising technique that will assist in the analysis of outcomes following transplantation... - Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costsStephanie J Lee
Department of Adult Oncology and Department of Biostatistical Science, Dana Farber Cancer Institute, and the Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
Blood 100:2697-702. 2002..As prospective, randomized studies comparing methods of GVHD prophylaxis are performed, assessment of quality of life and costs should be included to fully understand the overall impact of each intervention... - Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantationThomas S Lin
Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
Transplantation 74:49-54. 2002..We sought to determine the effect of prior donor and patient CMV exposure on the incidence of CMV infection after TCD allogeneic HSCT... - Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cellsEmmanuel Zorn
Center for Hematologic Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Clin Cancer Res 8:2052-60. 2002..It was not detected before DLI. CONCLUSIONS: These results indicate that CD4+ DLI elicits a potent allogeneic response mediated by mHA-specific CD8+ T cells... - Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donorsDavid B Miklos
Department of Medical Oncology and Biostatistical Science, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115
Blood 103:353-9. 2004..These studies demonstrate that the immune response to mHA includes the generation of specific antibodies and suggests that the serologic response to these antigens may also be useful in the identification of new mHAs... - Graft-versus-host disease of the vulva and/or vagina: diagnosis and treatmentLisa B Spiryda
Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Medical Hospital, Harvard Medical School, Boston, Massachusetts, USA
Biol Blood Marrow Transplant 9:760-5. 2003..Vaginal GVHD can successfully be treated with topical cyclosporine when mild to moderate disease is present. Surgical lysis with topical cyclosporine is required when more severe disease ensues... - Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host diseaseDaniel J DeAngelo
Dana-Farber Cancer Institute, Department of Adult Oncology, Boston, Massachusetts 02115, USA
Clin Cancer Res 10:5065-71. 2004..Imantinib was far less effective in patients who relapsed with AP/BP-CML. Imatinib should be evaluated as either an alternative or as an adjunct to donor lymphocyte infusions for patients with SP-CML who relapse after SCT... - Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of ageEdwin P Alyea
Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
Blood 105:1810-4. 2005..052). Our experience suggests that, in patients over age 50, NST with fludarabine and low-dose busulfan leads to an overall outcome at least as good as that following myeloablative therapy... - Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantationJoseph H Antin
Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
Biol Blood Marrow Transplant 11:213-22. 2005..Pneumococcal conjugate vaccine is immunogenic in autoHCT patients and may be an effective strategy to prevent invasive disease after transplantation... - Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host diseaseEmmanuel Zorn
Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
Blood 106:2903-11. 2005..These findings support the development of new strategies to increase the number of Tregs following allogeneic hematopoietic stem cell transplantation to prevent or correct cGVHD... - Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trialStephanie J Lee
Dana Farber Cancer Institute, Boston, MA 02115, USA
Blood 104:1559-64. 2004..002). Both relapse- and GVHD-related mortality contributed to the increased mortality in the combination group. The combination of corticosteroids and daclizumab should not be used as initial therapy of acute GVHD... - Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remissionDavid B Miklos
Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, M530, Boston, MA 02115, USA
Blood 105:2973-8. 2005..Antibody response to Y-chromosome encoded histocompatibility antigens (H-Y antigens) was also associated with maintenance of disease remission (P < .0001). B cells may provide a new target for immune intervention in chronic GVHD... - Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantationVincent T Ho
Dana Farber Cancer Institute, 44 Binney St, D1B21, Boston, MA 02115, USA
Blood 104:1224-6. 2004..Eight of 24 patients (33%) are alive at 6.3 to 24.6 months (median, 7.2 months). Denileukin diftitox is tolerable and has promising activity in steroid-refractory acute GVHD... - Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantationCorey Cutler
Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Biol Blood Marrow Transplant 10:328-36. 2004..Mucositis was modest, engraftment was prompt, and transplant-related toxicity was modest. Methotrexate-free, sirolimus-based GVHD prophylactic regimens should be tested in randomized trials against the current standard of care... - Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantationEmmanuel Zorn
Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, M530, Boston, MA 02115, USA
J Exp Med 199:1133-42. 2004..The specificity for recipient male cells was mediated by the B cell response and not by donor T cells. This dual DBX/DBY antigen is the first mHA to be identified in the context of chronic GVHD... - Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapyAbba C Zubair
Connell O'Reilly Cell Manipulation Core Facility, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
Transfusion 44:253-61. 2004 - Phase II study of paclitaxel and carboplatin for malignant melanomaF Stephen Hodi
Adult Oncology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
Am J Clin Oncol 25:283-6. 2002..Comparisons with other treatment regimens and the search for additional active compounds against melanoma are needed... - CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cellsXiao Feng Yang
Center for Hematologic Oncology, Dana Farber Cancer Institute, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Cancer Res 62:5517-22. 2002..Moreover, given its expression and immunogenicity in a wide variety of malignancies, CML28 merits additional evaluation as a target for antigen-specific immunotherapy... - Chronic myelogenous leukemiaEllin Berman
University of Texas M. D. Anderson Cancer Center, USA
J Natl Compr Canc Netw 5:474-96. 2007 - Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosisRoberto Bellucci
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Blood 109:2001-7. 2007..Interestingly, the epitope specificity of these PDC-E2 autoantibodies was distinctive, suggesting that the mechanisms leading to loss of tolerance in the transplantation patients are distinct from PBC... - Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patientsF Stephen Hodi
Department of Adult Oncology, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 100:4712-7. 2003..These findings suggest that CTLA-4 antibody blockade increases tumor immunity in some previously vaccinated cancer patients... - Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunityGerald P Linette
Division of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital, Boston, 02114, USA
Clin Cancer Res 11:7692-9. 2005..CONCLUSION: The high rate of immunization as measured by three independent assays and the occurrence of clinical regression support continued investigation of G280-9V peptide as a candidate epitope in melanoma vaccine formulations...